<unk>  (SSR-240,600) is a drug developed by Sanofi-Aventis which was one of the first compounds developed that acts as a potent and selective antagonist for the NK1 receptor. While<unk>  itself did not proceed beyond early clinical trials and was never developed for clinical use in humans, promising animal results from this and related compounds have led to a number of novel drugs from this class that have now been introduced into medical use.
Burapitant
Veristrat
Beractant
Pleconaril
Umbralisib
Belinostat
Mitapivat
Snoezelen